Name: Ethan (pseudonym)
Age: 8 years old
Nationality: Singapore
Diagnosis: Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), CD19-negative relapse after CD19 CAR-T therapy.
Treatment Hospital: Shanghai Children's Medical Center
In the field of childhood leukemia treatment, CAR-T cell therapy has brought hope to countless families. But when this "living drug" also fails, patients' families face an abyss of near despair. Ethan's story tells how we helped a family find a "backup plan" within the Chinese approach amidst despair.
1. When CD19 CAR-T therapy fails
Ethan was diagnosed with B-ALL at age 8 and relapsed two years after chemotherapy. In Singapore, he received CAR-T cell therapy targeting CD19, which was the most advanced treatment in the world at the time. However, three months after CAR-T therapy, his leukemia relapsed again, and this time the cancer cells exhibited "antigen escape"—they no longer expressed CD19, meaning that CD19 CAR-T cells could no longer recognize and attack them. Doctors in Singapore informed his parents that there was no standard treatment option and recommended palliative care.
2. Our Value: Providing a "navigation map" for accurate decision-making in seemingly incurable situations.
Ethan's parents came to us in desperation, with only one request: "Are there any other CAR-T therapies? Are there any other targets?"
Faced with this weighty expectation, our role is not that of "medical detectives," but rather the most efficient "information navigators." We deeply understand that in the complex situation of "antigen escape," any preconceived judgment is irresponsible. What we can do is ensure that top experts have the clearest and most complete decision-making basis when they take over the case.
Our first step was to refine the fragmented medical records into a structured "decision support summary." Our medical case manager compiled Ethan's latest bone marrow flow cytometry report, previous chemotherapy regimens, CAR-T treatment details, and post-relapse tests into a logically clear "CD19-negative relapsed B-ALL Case Summary." The core value of this summary lies in objectively and completely presenting the key information of "CD19 antigen loss," while simultaneously annotating the expression of all other detectable immunophenotypes (such as CD22 and CD20) in the flow cytometry report. We do not make any inferences about the "availability of this target," but only ensure that experts can clearly see the complete immunophenotypic atlas.
Before the patient's departure, we completed precise resource matching based on cutting-edge information. Based on the core need presented in this abstract—"CD19 negative, seeking other targets"—we quickly reviewed CAR-T clinical trials and published cutting-edge clinical data for CD19-negative B-ALL globally. We found that China is a world leader in the research and clinical application of CD22 CAR-T cell therapy, with Shanghai Children's Medical Center possessing mature clinical experience. We matched Ethan's family with an expert team from that center and assisted in arranging remote video consultations.
During the remote consultation, we assisted the family in communicating effectively with experts. We deeply understand that families in despair need honest and clear information most of all. Before the consultation, we helped Ethan's parents compile a list of "five most important questions to ask," including: the bridging therapy plan, the risks of cytokine storm, and long-term survival data. During the consultation, experts from Shanghai Children's Medical Center provided a professional assessment based on the summary we provided and candidly explained the hopes and risks of treatment. This communication allowed Ethan's parents to see a glimmer of light in the darkness.
3. During and after diagnosis: Comprehensive support from "bridging therapy" to "long-term follow-up"
After arriving in China, Ethan underwent bridging chemotherapy under the guidance of an expert team at Shanghai Children's Medical Center, followed by an infusion of CD22 CAR-T cells. Throughout the process, our bilingual coordinator provided full-time support, assisting his parents in communicating with the medical team and recording daily vital signs and adverse reactions.
Post-treatment services and follow-up: Follow-up after CAR-T therapy is crucial for determining long-term efficacy. We established a "CAR-T Post-operative Long-Term Follow-up File" for Ethan, the core task of which is to implement the monitoring plan developed by experts at Shanghai Children's Medical Center. We coordinated with hospitals in Singapore to conduct monthly bone marrow MRD tests on Ethan, and synchronized the results with experts in China. Once the MRD turns positive, we immediately activate the alert mechanism to assist experts in deciding whether maintenance therapy or a second infusion is necessary. In addition, we also assisted in implementing the "Immune Reconstitution Monitoring Plan," regularly tracking his immunoglobulin levels and CD4+ T cell counts to prevent infection.
4. Therapeutic Effects and Insights
One month after the CD22 CAR-T infusion, Ethan's bone marrow MRD turned negative, and he achieved his second complete remission. One year after the transplant, he remains disease-free. His father said in a message to us, "When the doctors in Singapore said 'there's nothing more they can do,' our world collapsed. You helped me find experts in China. You gave Ethan a second life."